Coloplast interim CEO Lars Rasmussen will step down from the Board at the upcoming Annual General Meeting

Core Points - Coloplast's interim CEO Lars Rasmussen will not seek re-election to the Board at the upcoming Annual General Meeting on December 4, 2025 [1] - Lars Rasmussen has served Coloplast for nearly four decades, including 10 years as CEO and 7 years as Chair of the Board, significantly contributing to its transformation into a leading global MedTech company [2][5] - The company is entering a new phase with the implementation of its Impact4 strategy, which aims to enhance customer focus and support the goal of helping 4 million people in the long term [4][7] Leadership Transition - Jette Nygaard-Andersen will continue as interim Chair of the Board, leading the company during this transition period [5] - Niels B. Christiansen is proposed as a new Board member, with expectations to become Chair by December 2026 [6][7] - The Board is focused on strong succession planning and continuity, with unanimous support for the announced leadership changes [8] Company Mission and Vision - Coloplast's mission is to make life easier for individuals with intimate healthcare needs, driven by a commitment to innovation and empathy [11] - The company operates in various business areas, including Ostomy Care, Continence Care, Voice and Respiratory Care, Wound and Tissue Repair, and Interventional Urology [11]